IL-22Ra2 Levels Remain Elevated in People with Cystic Fibrosis despite Modulator Therapy
Am J Respir Crit Care Med
.
2024 Nov 1;210(9):1158-1161.
doi: 10.1164/rccm.202402-0458RL.
Authors
Christine M Bojanowski
1
,
Stella E Lee
2
,
Giraldina Trevejo-Nunez
3
,
Jennifer M Bomberger
4
,
Robert P Schleimer
5
,
Milene T Saavedra
6
,
Jay K Kolls
7
Affiliations
1
Section of Pulmonary Diseases, Critical Care and Environmental Medicine and.
2
Division of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts.
3
Division Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
4
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
5
Division of Allergy and Immunology, Feinberg School of Medicine, Chicago, Illinois; and.
6
Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado.
7
Center for Translational Research in Infection and Inflammation, Tulane University School of Medicine, New Orleans, Louisiana.
PMID:
39197091
DOI:
10.1164/rccm.202402-0458RL
No abstract available
Publication types
Letter
Grants and funding
006699G223/Cystic Fibrosis Foundation/United States
R35HL139930/HL/NHLBI NIH HHS/United States
Gilead RSP in Cystic Fibrosis/Gilead Research Scholars/United States